On December 24, Nemans Health Foods Holdings Limited submitted a prospectus to the Hong Kong Stock Exchange, seeking to list on the Main Board. The sole sponsor for the listing is Caitong International. Nemans primarily engages in the marketing, sales, and distribution of finished nutritional products in China. These products, sold under the proprietary brands “Niu Man Si” and “Nemans”(English brand), are categorized into five major groups: algae oil DHA, probiotics, vitamins, multi-nutritional supplements, and algae-based calcium products. The company employs an OEM model for manufacturing and branding its products.
In 2023, Nemans reported a revenue of RMB 427 million (approximately USD 58.5 million) and a net profit of RMB 159 million (approximately USD 21.8 million), achieving a net profit margin of 37.36%. In the first half of 2024, the revenue reached RMB 146 million (approximately USD 20 million), with a net profit of RMB 45 million (approximately USD 6.2 million), marking a net profit margin of 31%.
Previously, Nemans had submitted applications for listing on April 8, 2019, October 28, 2019, July 27, 2020, February 8, 2021, December 29, 2023, and September 30, 2024, without success. This approval marks a milestone, paving the way for Nemans to proceed with its IPO. (Source: STCN)
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE